# Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

> **NCT01173913** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 57 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** ModraDoc001 10mg capsules
- **DRUG:** ModraDoc003 10mg tablets and ModraDoc004 10/50 mg
- **DRUG:** ModraDoc006 10 mg tablet

## Key facts

- **NCT ID:** NCT01173913
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2016-10-04
- **Final completion:** 2017-01-26
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01173913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01173913, "Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01173913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*